To combat the global pandemic, vaccines have been developed and authorized for use with unprecedented speed. How has a vaccine been successfully manufactured and what role did regulations play in its development? How have global and local regulations shaped this solution to our current global health crisis? What effects have agency action and pharmaceutical companies’ transparency had on public trust in the vaccine? Join us for a conversation with Professor Rachel Sachs from Washington University in St. Louis School of Law and Dr. Margaret Ruesch, Vice President of Analytical Research and Development, Biotherapeutics Pharmaceutical Sciences at Pfizer. Professor Stephen Yelderman, Co-Faculty Director of Notre Dame Law School's Program on IP & Technology Law, will moderate.
If you are interested in attending this event, please email Dr. Felicia Caponigri, Program Director of the Program on IP & Technology Law, at email@example.com.